Janus Henderson Group PLC reduced its holdings in shares of MEDNAX Inc (NYSE:MD) by 0.9% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 313,859 shares of the company’s stock after selling 2,967 shares during the period. Janus Henderson Group PLC’s holdings in MEDNAX were worth $14,646,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also made changes to their positions in the company. Eagle Boston Investment Management Inc. boosted its stake in MEDNAX by 5.2% during the 3rd quarter. Eagle Boston Investment Management Inc. now owns 257,103 shares of the company’s stock worth $11,996,000 after purchasing an additional 12,595 shares during the period. Swiss National Bank boosted its stake in MEDNAX by 1.1% during the 3rd quarter. Swiss National Bank now owns 164,800 shares of the company’s stock worth $7,690,000 after purchasing an additional 1,800 shares during the period. Commonwealth Bank of Australia acquired a new stake in MEDNAX during the 3rd quarter worth $531,000. Prudential Financial Inc. boosted its stake in MEDNAX by 1.4% during the 3rd quarter. Prudential Financial Inc. now owns 744,763 shares of the company’s stock worth $34,751,000 after purchasing an additional 10,085 shares during the period. Finally, Fort Washington Investment Advisors Inc. OH boosted its stake in MEDNAX by 19.0% during the 3rd quarter. Fort Washington Investment Advisors Inc. OH now owns 432,320 shares of the company’s stock worth $20,172,000 after purchasing an additional 69,119 shares during the period. 98.16% of the stock is currently owned by hedge funds and other institutional investors.
MD has been the subject of a number of recent research reports. Leerink Swann upgraded shares of MEDNAX from a “market perform” rating to an “outperform” rating in a research note on Monday, September 24th. Robert W. Baird cut their price objective on shares of MEDNAX from $50.00 to $48.00 and set a “neutral” rating for the company in a research report on Friday, October 19th. ValuEngine downgraded shares of MEDNAX from a “sell” rating to a “strong sell” rating in a research report on Thursday, November 1st. BMO Capital Markets cut their price objective on shares of MEDNAX from $48.00 to $43.00 and set a “market perform” rating for the company in a research report on Friday, November 2nd. Finally, UBS Group initiated coverage on shares of MEDNAX in a research report on Friday, November 16th. They set a “sell” rating and a $37.00 price objective for the company. Three analysts have rated the stock with a sell rating, nine have assigned a hold rating and four have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $51.20.
MEDNAX (NYSE:MD) last announced its quarterly earnings data on Thursday, November 1st. The company reported $0.94 EPS for the quarter, missing the Zacks’ consensus estimate of $0.97 by ($0.03). The firm had revenue of $896.60 million for the quarter, compared to analysts’ expectations of $908.15 million. MEDNAX had a return on equity of 10.45% and a net margin of 9.50%. The firm’s quarterly revenue was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.87 EPS. On average, equities research analysts forecast that MEDNAX Inc will post 3.51 earnings per share for the current year.
MEDNAX, Inc, together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology, pediatric cardiology, and other pediatric subspecialties physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care; and acute and chronic pain management services.
See Also: What is a Tariff?
Want to see what other hedge funds are holding MD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MEDNAX Inc (NYSE:MD).
Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.